Kusajili – Clinical trials directory

Result of your search per sponsor: SciClone Pharmaceuticals, Inc

Woman and Man Max 99 years
SciClone Pharmaceuticals, Inc Update Il y a 4 ans

A Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Unresectable, Locally Advanced, or Metastatic Pancreatic Adenocarcinoma To compare the overall survival (OS) distributions of RP101 and gemcitabine to placebo and gemcitabine in subjects with unresectable, locally advanced or metastatic pancreatic adenocarcinoma.

Country None
organs None
Specialty None

unknown

More information